Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

es' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's drug development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel will successfully treat migraine pain, that NGX267 will successfully treat the symptoms of cognitive impairment associated with schizophrenia, that NGX267 will successfully treat xerostomia or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31,2006 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is lik
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 28, 2015  Moerae Matrix Inc. announced today ... trial with MMI-0100, a first-in-class inhibitor of MAPKAP ... pulmonary disorders characterized by inflammation and fibrosis.  The ... , is a double-blind, two-way cross-over design ... and tolerability of MMI-0100 when given via inhalation ...
(Date:7/28/2015)... ZIONA, Israel , July 28, ... OTC:CQPTY), a regenerative medicine company utilizing its proprietary ... announced that Shomrat Shurtz has been appointed Senior ...      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ) ... years of experience in marketing, regulatory and business ...
(Date:7/27/2015)... ... 27, 2015 , ... This is a professional and in-depth ... overview of the industry including definitions, classifications, applications and industry chain structure. The ... landscape analysis, and key regions development status. Development policies and plans are discussed ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... network Monday. The venture will bring the world’s most efficient gas dissolution technology ... equipment and technologies to both the industrial and municipal markets. With offices located ...
Breaking Biology Technology:Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2CollPlant Names Shomrat Shurtz Senior Director of Business Development 22015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3BlueInGreen Brings Water Treatment Technology to Florida 2
... with ,no strings attached, SEATTLE, Sept. 25 ... Hutchinson Cancer Research Center, is among 24 recipients ... annually by the John,D. and Catherine T. MacArthur ... "no-strings-attached" support. Roth, a member of the ...
... (Nasdaq: EMIS ) has agreed to accept ... LLY ) to settle the pending litigation between ... a Stipulation of Dismissal with,Prejudice of their litigation ... District of Indiana. Additional terms and conditions of ...
... DIEGO, Sept. 25 SpectraScience, Inc. (OTC,Bulletin Board: SCIE) ... to its Board of Directors. Before entering the private,sector ... career,in public service. In 1966 he won a seat ... in 1973 and Assembly minority,leader in 1981. Elected governor ...
Cached Biology Technology:Basic Scientist Mark Roth Wins MacArthur Fellowship 2Basic Scientist Mark Roth Wins MacArthur Fellowship 3Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation 2SpectraScience Appoints the Honorable Tommy Thompson to its Board of Directors 2SpectraScience Appoints the Honorable Tommy Thompson to its Board of Directors 3
(Date:7/23/2015)... Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... today reported financial results for its second quarter ended June ... of 2015 was $4.5 million, a decrease of 33% compared ... income in the second quarter of 2015 was $0.3 million, ... or $0.04 per diluted share, in the same period a ...
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/13/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced sampling of ClearPad ® 4300, ... (TDDI) product targeting smartphones and tablets. This new ... , best-in-class touch controller IP and systems ... in the company,s Japan Design Center. TDDI enables ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... laboratory antibodies derived from chimpanzees and humans may provide ... serious complications that can occur following smallpox vaccination--and possibly ... study, led by researchers with the National Institute of ... Institutes of Health (NIH), appears online this week in ...
... state-of-the-art anti-aging technologies may extend human lifespans at an ... and economic challenges, says biologist Shripad Tuljapurkar of Stanford ... would have major implications for the global community in ... Professor of Population Studies, will give a talk Feb. ...
... theory of genetic revolution , introduced in 1954, ... , Mayr believed that genes interacted with one another, ... an interaction of natural selection with genetic drift that ... , Detractors of the theory object to what they ...
Cached Biology News:Mice studies illustrate potential of chimp/human antibodies to protect against smallpox 2Mice studies illustrate potential of chimp/human antibodies to protect against smallpox 3World faces challenge as life expectancies lengthen, scientist says 2World faces challenge as life expectancies lengthen, scientist says 3World faces challenge as life expectancies lengthen, scientist says 4Ernst Mayr's theory illustrated in genetic epidemiology studies 2Ernst Mayr's theory illustrated in genetic epidemiology studies 3Ernst Mayr's theory illustrated in genetic epidemiology studies 4
... Anti-NY-ESO-1, clone E978 ... : NM_001327 Immunogen ... protein Formulation: mouse ascites ... Quality Assurance: routinely evaluated ...
... to Opsin 1 ( Abpromise for all ... peptide: YEDSTHASIFTYT, corresponding to amino acids 14/26 of ... corresponding to amino acids 18/30 of tiger red ... immunogen. Entrez Gene ID: ...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Request Info...
Biology Products: